Semaglutide contraindications include personal or family history of medullary thyroid cancer, MEN2, pancreatitis, and pregnancy. Learn who should avoid it.
Semaglutide contraindications are the specific medical conditions that make the medication unsafe, and the FDA-approved labels for Ozempic, Wegovy, and Rybelsus list three: a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2 (MEN2), and a known hypersensitivity to semaglutide or any of its ingredients. Other situations — pregnancy, past pancreatitis, severe gastroparesis — are handled as warnings or precautions rather than absolute bans. That difference decides whether a prescriber can still offer the drug with monitoring or needs to choose something else.
Contraindication vs. Warning: Why the Distinction Matters
A contraindication means a treatment should not be used at all, because the risk clearly outweighs any benefit. A warning or precaution means the drug can still be prescribed, but it requires monitoring, dose adjustment, or a candid conversation about risk.
News coverage of GLP-1 drugs often collapses these two categories. The boxed warning about thyroid C-cell tumors applies to every patient who takes semaglutide, while the actual contraindication applies only to people with a specific personal or family history.
The Three Labeled Semaglutide Contraindications
Personal or family history of medullary thyroid cancer
In rodent studies, semaglutide caused thyroid C-cell tumors at doses that produced drug exposure similar to human therapeutic levels. Regulators could not rule out a comparable effect in people, so the label carries both a boxed warning and a contraindication for anyone with a personal or family history of medullary thyroid carcinoma (MTC).
Because MTC can run in families, a parent, sibling, or child with the diagnosis counts. Tell your prescriber before starting or refilling any semaglutide product.
Multiple endocrine neoplasia syndrome type 2 (MEN2)
MEN2 is an inherited syndrome that sharply raises the lifetime risk of medullary thyroid cancer. People with a confirmed RET gene mutation or a clinical MEN2 diagnosis are excluded from semaglutide therapy, and most clinicians will not make exceptions.
Known hypersensitivity to semaglutide or its excipients
Anaphylaxis, angioedema, and severe skin reactions have been reported with semaglutide. Anyone who has experienced a serious reaction should not restart the drug. Since reactions can involve inactive compounds as well, reviewing semaglutide ingredients is a reasonable step for patients with a history of drug allergies.
Product-by-Product Comparison
Ozempic, Wegovy, and Rybelsus carry different approved uses but identical label contraindications.
| Product | Approved use | Label contraindications | Additional notes |
|---|---|---|---|
| Ozempic (injectable) | Type 2 diabetes, adults | Personal or family history of MTC; MEN2; hypersensitivity | Not for type 1 diabetes; boxed warning applies |
| Wegovy (injectable) | Chronic weight management, adults and ages 12+ | Same three | Stop at least 2 months before a planned pregnancy |
| Rybelsus (oral) | Type 2 diabetes, adults | Same three | Take on an empty stomach with a small amount of water |
Pregnancy and Breastfeeding
Semaglutide is not recommended during pregnancy. Weight-loss treatment with Wegovy is stopped at least two months before a planned pregnancy, and anyone who becomes pregnant while taking semaglutide should contact their prescriber promptly.
Data on semaglutide in breast milk are limited, so breastfeeding is generally treated as a reason to pause treatment as well. People planning a pregnancy should discuss alternatives with an obstetrician and the prescribing clinician together.
Conditions That Call for Caution, Not a Hard Stop
Several conditions appear in the warnings sections rather than the contraindications. They usually mean extra monitoring, a slower dose increase, or a different drug.
- History of pancreatitis: semaglutide should be stopped if pancreatitis is suspected, and a prior episode makes many clinicians cautious.
- Severe gastroparesis or delayed stomach emptying: GLP-1 drugs slow gastric emptying, which can worsen symptoms.
- Gallbladder disease: gallstones and cholecystitis are reported more often during rapid weight loss.
- Diabetic retinopathy: rapid blood sugar improvement can temporarily worsen eye disease.
- Kidney impairment: dehydration from vomiting or diarrhea can stress the kidneys.
- Mood changes or a history of suicidal thoughts: European regulators added a warning after reviewing case reports.
Most people tolerate semaglutide with manageable semaglutide side effects such as nausea, vomiting, diarrhea, and constipation, especially during dose escalation. Worries about semaglutide side effects cancer risk come largely from the rodent thyroid findings, and human data so far have not confirmed the same tumor risk — which is why the response was a boxed warning and a narrow contraindication rather than a broad restriction.
What Happens If You Are Contraindicated
If any of the three label contraindications apply, the usual next step is a non-GLP-1 option: older diabetes medications, other weight-management drugs, or a structured lifestyle program. Switching to a different GLP-1 is not a workaround, because the MTC and MEN2 restriction is a class-wide labeling requirement.
Investigational combinations such as cagrilintide and semaglutide generally follow the same exclusion criteria in clinical trials. Research peptides sometimes mentioned alongside GLP-1s, including the pairing of aod 9604 and semaglutide, are not FDA-approved for human use and should not be treated as a safe substitute.
The Bottom Line
Semaglutide is contraindicated in people with a personal or family history of medullary thyroid cancer, MEN2, or a serious allergic reaction to the drug or its ingredients. Pregnancy, pancreatitis history, gastroparesis, and kidney problems are reasons for caution and monitoring rather than automatic disqualification. Anyone in either category should review their medical history with a healthcare professional before starting treatment.
Frequently Asked Questions
Is pancreatitis a contraindication for semaglutide?
No. A history of pancreatitis is listed under warnings and precautions on the semaglutide label, not under contraindications. That means the drug can sometimes still be prescribed with careful monitoring, but it should be stopped right away if pancreatitis is suspected during treatment.
Can you take semaglutide if you have a family history of thyroid cancer?
Only medullary thyroid carcinoma is an absolute contraindication. A family history of papillary or follicular thyroid cancer does not appear on the label as a contraindication, but it is still worth discussing with your prescriber, who may recommend screening or a different medication.
Is semaglutide safe during pregnancy?
Semaglutide is not recommended during pregnancy, and the Wegovy label directs patients to stop the drug at least two months before a planned pregnancy. Anyone who becomes pregnant while taking semaglutide should contact their prescriber and an obstetrician as soon as possible to review next steps.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.